New Blood Test Technology Poised To Replace Invasive Biopsies: A Forecast Of Market Growth.

(MENAFN- GlobeNewsWire - Nasdaq) The market offers significant opportunities in non-invasive cancer diagnostics using in vitro blood tests, with potential to replace traditional biopsies. Key areas include screening, diagnosis, therapy selection, and recurrence monitoring across various cancers, alongside detailed geographic and application-specific insights.

Dublin, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, Including Executive and Consultant Guides 2025-2029" has been added to ResearchAndMarkets's offering.

The latest report delves into the Screening, Diagnostic, Therapy Selection, and Minimal Residual Disease Market Potential, providing a comprehensive analysis. This report examines price and volume outlooks by cancer type, offering invaluable insights for stakeholders.

Explore the frontier of cancer diagnostics with technologies revolutionizing the field, including Circulating Tumor Cells, Cell Free DNA, and Exosomes. Discover the technological advancements spawning widespread cancer screening tests, and assess the opportunities alongside potential pitfalls. Understand growth expectations and the market's ultimate potential size as these technologies redefine the industry landscape.

In vitro blood testing has ushered in a new era for cancer diagnostics, rapidly outpacing traditional methods. With the capability of forming precise disease identifications from blood samples, this technology stands ready to replace costly and invasive surgical biopsies. Our report sheds light on the current growth phase of the market and forecasts the future impact on the healthcare industry. It explores anticipated market size over the next five years with a detailed analysis by country, cancer type, and usage category: screening, diagnosis, therapy selection, and recurrence monitoring.

Uncover detailed breakouts featuring 15 countries and 4 key regions, segmented into specific cancer types, including Lung, Breast, Colorectal, Prostate, and Cervical. Additionally, understand the nuances of Screening/Early Detection, Diagnostic, Therapy Monitoring, and Recurrence Monitoring sectors. Whether you're assessing investment decisions or valuations, our findings equip you with the data needed to approach the market confidently, harnessing the latest insights for strategic planning.

Prepare for the future with our five-year market forecasts, an essential tool for anyone navigating the intricate landscape of cancer diagnostics technology and its transformative effects across global healthcare sectors.

Companies Featured

• Abbott Laboratories
• AccuraGen Inc.
• Acuamark Diagnostics
• Admera Health, LLC
• Agilent
• Amoy Diagnostics Co., Ltd.
• Anchor Dx
• ANGLE plc
• Applied DNA Sciences
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics (Danaher)
• Becton, Dickinson and Company
• Berkley Lights
• BGI Genomics Co. Ltd
• BillionToOne
• Bio-Rad Laboratories, Inc
• Bio-Techne
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bioview
• Burning Rock
• Cardiff Oncology
• CareDx
• Caris Molecular Diagnostics
• CellCarta
• CellMax Life
• Cepheid (Danaher)
• Circulogene
• Cizzle Biotech
• Clearbridge Biomedics
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Dxcover
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Exact Sciences
• Fluxion Biosciences (Cell Microsystems)
• Freenome
• Fyr Diagnostics
• GeneFirst Ltd.
• Genetron Holdings
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• Haystack Oncology (Quest Dx)
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• INOVIQ
• Invitae Corporation
• J&J Innovative Medicine
• Lucence Health
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics
• Nanostring
• NantHealth, Inc.
• Natera
• NeoGenomics
• Novogene
• On-Chip Biotechnologies
• Oncimmune
• Oncocyte
• OncoDNA
• Oxford Nanopore Technologies
• PamGene
• Panagene
• Personalis
• PGDx (Labcorp)
• PrecisionMed
• Predicine
• Predictive Oncology
• Prenetics
• Promega
• Qiagen
• Rarecells SAS
• RareCyte
• Revvity
• Roche Diagnostics
• Saga Diagnostics
• Screencell
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Standard BioTools
• Stilla Technologies
• Superfluid Dx
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Todos Medical
• Ultima Genomics
• Veracyte
• VolitionRX
• Vortex Biosciences

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08122025004107003653ID1110451859